Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment-Reference-Cited by-同舟云学术

Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment

Published:2019-05-07 Issue:9 Volume:25 Page:995-1005
ISSN:1755-5930
Container-title:CNS Neuroscience & Therapeutics
language:en
Short-container-title:CNS Neurosci Ther

Author:

Mansilla María José¹²^ORCID,Navarro‐Barriuso Juan¹²,Presas‐Rodríguez Silvia³⁴,Teniente‐Serra Aina¹²,Quirant‐Sánchez Bibiana¹²^ORCID,Ramo‐Tello Cristina³⁴,Martínez‐Cáceres Eva María¹²

Affiliation:

1. Immunology Division, LCMN Germans Trias i Pujol University Hospital and Research Institute, Campus Can Ruti Badalona Spain

2. Department of Cellular Biology, Physiology and Immunology Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain

3. Multiple Sclerosis Unit, Department of Neurosciences Germans Trias i Pujol University Hospital Badalona Spain

4. Department of Medicine Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain

Funder

Instituto de Salud Carlos III

European Regional Development Fund

Generalitat de Catalunya

Publisher

Wiley

Subject

Pharmacology (medical),Physiology (medical),Psychiatry and Mental health,Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cns.13142

Reference33 articles.

1. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

2. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

3. Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action

4. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

5. Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cytokine networks in neuroinflammatory diseases;Nature Reviews Drug Discovery;2024-09-11

2. High frequency of circulating non-classical monocytes is associated with stable remission in relapsing-remitting multiple sclerosis;Immunological Medicine;2024-03-27

3. Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients;Frontiers in Immunology;2023-07-07

4. Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method;Therapeutic Advances in Neurological Disorders;2023-01

5. Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS;Journal of Neuroimmunology;2021-12